Trial Profile
A Phase III Observer-blind, Randomized, Controlled, Single-coordinating Center Study to Investigate Immunogenicity and Safety of a Monovalent Glycoprotein-conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children in China, According to the Recommended Regimen of 1 Dose.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Apr 2013
Price :
$35
*
At a glance
- Drugs TAK 816 (Primary) ; Hib vaccine conjugate
- Indications Haemophilus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Novartis
- 21 May 2010 New trial record